Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors

AIDS

Volumn 23, Issue 14, 2009, Pages 1799-1806

  Archin, Nancie M ^a   Keedy, Kara S ^a   Espeseth, Amy ^c   Dang, Herbert ^c   Hazuda, Daria J ^c   Margolis, David M ^a,b,d  

^a Department of Medicine ^*  (United States)

^b IL   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Histone deacetylase; HIV; Latency; Long terminal repeat; Resting CD4 T cells

Indexed keywords

HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE INHIBITOR;

ACETYLATION; ARTICLE; CD4+ T LYMPHOCYTE; CELL ISOLATION; CHROMATIN; ENZYME INHIBITION; GENE EXPRESSION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; LONG TERMINAL REPEAT; PRIORITY JOURNAL; VIROGENESIS; VIRUS EXPRESSION; VIRUS LATENCY;

CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CHROMATIN; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; HELA CELLS; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE INHIBITORS; HIV LONG TERMINAL REPEAT; HIV-1; HUMANS; JURKAT CELLS; VIRUS LATENCY; VIRUS REPLICATION;

EID: 70249100307     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32832ec1dc     Document Type: Article

References (33)

1. Chun TW, Stuyver L, Mizell SB, Ehler LA, Mican JA, Baseler M, et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A 1997; 94:13193-13197.
2. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997; 278:1295-1300.
3. Wong JK, Hezareh M, Gunthard HF, Havlir DV, Ignacio CC, Spina CA, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997; 278:1291-1295.
4. Pazin MJ, Sheridan PL, Cannon K, Cao Z, Keck JG, Kadonaga JT, et al. NF-kappa B-mediated chromatin reconfiguration and transcriptional activation of the HIV-1 enhancer in vitro. Genes Dev 1996; 10:37-49.
5. Van Lint C, Emiliani S, Ott M, Verdin E. Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation. EMBO J 1996; 15:1112-1120.
6. El Kharroubi A, Piras G, Zensen R, Martin MA. Transcriptional activation of the integrated chromatin-associated human immunodeficiency virus type 1 promoter. Mol Cell Biol 1998; 18:2535-2544.
7. Williams SA, Greene WC. Regulation of HIV-1 latency by T-cell activation. Cytokine 2007; 39:63-74.
8. Glozak MA, Seto E. Histone deacetylases and cancer. Onco-gene 2007; 26:5420-5432.
9. Coull JJ, Romerio F, Sun JM, Volker JL, Galvin KM, Davie JR, et al. The human factors YY1 and LSF repress the human immunodeficiency virus type 1 long terminal repeat via recruitment of histone deacetylase 1. J Virol 2000; 74:6790-6799.
10. Imai K, Okamoto T. Transcriptional repression of human immunodeficiency virus type 1 by AP-4. J Biol Chem 2006; 281:12495-12505. (Pubitemid 43855336)
11. Williams SA, Chen LF, Kwon H, Ruiz-Jarabo CM, Verdin E, Greene WC. NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation. EMBO J 2006; 25:139-149.
12. Jiang G, Espeseth A, Hazuda DJ, Margolis DM. c-Myc and Sp1 contribute to proviral latency by recruiting histone deacetylase 1 to the human immunodeficiency virus type 1 promoter. J Virol 2007; 81:10914-10923.
13. Tyagi M, Karn J. CBF-1 promotes transcriptional silencing during the establishment of HIV-1 latency. EMBO J 2007; 26:4985-4995.
14. Marban C, Suzanne S, Dequiedt F, de Walque S, Redel L, Van Lint C, et al. Recruitment of chromatin-modifying enzymes by CTIP2 promotes HIV-1 transcriptional silencing. EMBO J 2007; 26:412-423.
15. Malcolm T, Chen J, Chang C, Sadowski I. Induction of chro-mosomally integrated HIV-1 LTR requires RBF-2 (USF/TFII-I) and Ras/MAPK signaling. Virus Genes 2007; 35:215-223.
16. Coull JJ, He G, Melander C, Rucker VC, Dervan PB, Margolis DM. Targeted derepression of the human immunodeficiency virus type 1 long terminal repeat by pyrrole-imidazole poly-amides. J Virol 2002; 76:12349-12354.
17. Ylisastigui L, Coull JJ, Rucker VC, Melander C, Bosch RJ, Brodie SJ, et al. Polyamides reveal a role for repression in latency within resting T cells of HIV-infected donors. J Infect Dis 2004; 190:1429-1437.
18. Ylisastigui L, Archin NM, Lehrman G, Bosch RJ, Margolis DM. Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression. AIDS 2004; 18:1101-1108.
19. Archin NM, Espeseth A, Parker D, Cheema M, Hazuda D, Margolis DM. Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res Hum Retroviruses 2009; 25:207-212.
20. Kutsch O, Benveniste EN, Shaw GM, Levy DN. Direct and quantitative single-cell analysis of human immunodeficiency virus type 1 reactivation from latency. J Virol 2002; 76:8776-8786.
21. Kimpton J, Emerman M. Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene. J Virol 1992; 66:2232-2239.
22. Pescatore G, Kinzel O, Attenni B, Cecchetti O, Fiore F, Fonsi M, et al. Optimization of a series of potent and selective ketone histone deacetylase inhibitors. Bioorg Med Chem Lett 2008; 18:5528-5532.
23. Jones P, Altamura S, Chakravarty PK, Cecchetti O, De Francesco R, Gallinari P, et al. A series of novel, potent, and selective histone deacetylase inhibitors. Bioorg Med Chem Lett 2006; 16:5948-5952.
24. Hideshima T, Bradner JE, Wong J, Chauhan D, Richardson P, Schreiber SL, et al. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci U S A 2005; 102: 8567-8572.
25. Jones P, Bottomley MJ, Carfi A, Cecchetti O, Ferrigno F, Lo Surdo P, et al. 2-Trifluoroacetylthiophenes, a novel series of potent and selective class II histone deacetylase inhibitors. Bioorg Med Chem Lett 2008; 18:3456-3461. (Pubitemid 351728088)
26. Muraglia E, Altamura S, Branca D, Cecchetti O, Ferrigno F, Orsale MV, et al. 2-Trifluoroacetylthiophene oxadiazoles as potent and selective class II human histone deacetylase inhibitors. Bioorg Med Chem Lett 2008; 18:6083-6087.
27. Archin NM, Eron JJ, Palmer S, Hartmann-Duff A, Martinson JA, Wiegand A, et al. Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4R T cells. AIDS 2008; 22:1131-1135.
28. Vaquero A, Scher M, Reinberg D. Biochemistry of multiprotein HDAC complexes. In: Verdin E. editor. Histone deacetylases transcriptional regulation and other cellular functions. Totowa, New Jersey: Humana Press; 2006. p. 23.
29. Yoshida N, Omoto Y, Inoue A, Eguchi H, Kobayashi Y, Kur-osumi M, et al. Prediction of prognosis of estrogen receptor-positive breast cancer with combination of selected estrogen-regulated genes. Cancer Sci 2004; 95:496-502.
30. Keedy KS, Archin NM, Gates AT, Espeseth A, Hazuda DJ, Margolis DM. A limited group of class I histone deacetylases act to repress human immunodeficiency virus type-1 expression. J Virol 2009; 83:4749-4756.
31. Zhang W, Kone BC. NF-kappaB inhibits transcription of the H(R)-K(R)-ATPase alpha(2)-subunit gene: role of histone dea-cetylases. Am J Physiol Renal Physiol 2002; 283:F904-F911.
32. Westendorf JJ, Zaidi SK, Cascino JE, Kahler R, van Wijnen AJ, Lian JB, et al. Runx2 (Cbfa1, AML-3) interacts with histone deacetylase 6 and represses the p21(CIP1/WAF1) promoter. Mol Cell Biol 2002; 22:7982-7992.
33. Girdwood D, Bumpass D, Vaughan OA, Thain A, Anderson LA, Snowden AW, et al. P300 transcriptional repression is mediated by SUMO modification. Mol Cell 2003; 11:1043-1054.